pharma · Hypertriglyceridemia · Asthma · GRCE
Grace Therapeutics
Grace Therapeutics trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.
3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA HQ
18 Employees
Public company Type
GRCE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
- Employees
- 18
- Programs
- 29
- Drugs
- 37
- Patents
- 34
Grace Therapeutics clinical trials
Registry index of 30 ClinicalTrials.gov studies linked to Grace Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Grace Therapeutics trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Grace Therapeutics.
-
Zinc gluconate — Unknown
Clinical update -
Lipid Lowering Medication — Phase 2
Clinical update -
Ketamine — Phase 2
Clinical update -
Ketamine (Ketalar) — Phase 1
Clinical update -
Ketamine (Ketalar) Dose Level 1 — Phase 1
Clinical update -
Hydromorphone — Phase 1
Clinical update -
Fospropofol (Lusedra®) 6.5 — Unknown
Clinical update -
Desvenlafaxine Succinate — Approved
Clinical update